Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2022)

PSYCHOPHARMACOTHERAPY

Dynamics of cognitive impairments in patients with depressive disorders during combined and monotherapy with antidepressants

https://doi.org/10.21265/PSYPH.2022.60.1.004

Published 2022-03-30

  • R.V. Akhapkin

R.V. Akhapkin
Federal Medical Research Centre for Psychiatry and Narcology named after V.P. Serbsky

Abstract

Aim of the study was to compare the dynamics of cognitive impairment in patients with depressive disorders in the course of combined and monotherapy with antidepressants.

Material and methods. 198 patients with depressive disorders and 131 healthy volunteers who underwent psychodiagnostics of cognitive functions on the “Multipsychometer-05” complex, which contains the assessments of memory, attention, reaction speed, executive functions and thinking were included. The severity of affective symptoms in patients with depressive disorders was assessed using the MADRS.

Results. Antidepressant therapy has a positive effect on the reduction of cognitive impairment in patients with unipolar depressive disorders. The use of neurometabolic / neuroprotective drugs in combination with antidepressants had an objective justification in the form of pronounced decreases in memory and ability to concentrate, however, the positive effect on cognitive dysfunctions of the combination of neurometabolic / neuroprotective and thymoanaleptic drugs, on average, was comparable to antidepressant monotherapy. In case of clinical necessity, short-term prescription of tranquilizers / hypnotics can be recommended for patients with non-psychotic depressive disorders without significant risk of negative impact on cognitive processes.

Keywords

depressive disorders, cognitive impairment, antidepressants

PDF (Русский)

References

  1. Аведисова А.С., Спасова С.А. Влияние антидепрессантов на интеллектуально-мнестические функции как отражение их поведенческой токсичности // Социальная и клиническая психиатрия. – 2000. – № 2. – С. 30–34.
  2. Аведисова, А.С. Ремиссия при терапии антидепрессантами: признак стабилизации состояния или признак снижения активности процесса? // Психиатрия и психофармакотерапия. – 2008. – Т. 10, № 2. – С. 33-37.
  3. Краснов В.Н., Алфимова М.В., Мельникова Т.С., Фролов Краснов А.М. Взаимосвязи когнитивных и эмоциональных нарушений при депрессиях (обзор литературы) / // Доктор.Ру. – 2013. – № 5 (83). – С. 1–6.
  4. Мосолов С.Н., Потапов А.В., Шафаренко А.А., Костюкова А.Б., Забелина И.Н. Валидизация стандартизированных клинико-функциональных критериев ремиссии при шизофрении // Социальная и клиническая психиатрия. – 2011. – Т. 21, № 3. – С. 36-42.
  5. Baune B.T., Brignone M., Larsen K.G. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder // Int. J. Neuropsychopharmacol. – 2018. – Vol. 21(2). – P. 97-107.
  6. Baune B.T., Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – a systematic review // Psychiatry Res. – 2014. – Vol. 219. – P. 25-50.
  7. Biringer E. et al. Executive function improvement upon remission of recurrent unipolar depression // European Archieves of Psychiatry and Clinical Neuroscience. – 2005. – Vol. 255. – P. 373-380.
  8. Bortolato B. et al. Cognitive remission: a novel objective for the treatment of major depression? // BMC Medicine. – 2016. – Vol. 14. – 9.
  9. Buyukdura J.S., McClintock S.M., Croarkina P.E. Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment // Prog. Neuropsychopharmacol. Biol. Psychiatry. – 2011. – Vol. 35(2). – P. 395–409.
  10. Codony X. et al. 5-HT6 receptors and cognition // Curr Opin Pharmacol. – 2011. – Vol. 11. – P. 94–100.
  11. Duan Y. et al. The effect of short-term use of benzodiazepines on cognitive function of major depressive disorder patients being treated with antidepressants // J. Affect. Disord. – 2019. – Vol. 256. – P. 1-7.
  12. Fiorillo A. et al. Assessment and management of cognitive and psychosocial dysfunctions in patients with major depressive disorder: A Clinical Review // Front. Psychiatry. – 2018. – Vol. 9. – 493.
  13. Goldstein B.J., Goodnick P.J. Selective serotonin reuptake inhibitors in the treatment of affective disorders. Tolerability, safety and pharmacoeconomics // J Psychopharmacol. – 1998. – Vol. 12(3), Suppl. B. – P. 55–87.
  14. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) // Int Clin Psychopharmacol. – 1994. – Vol. 9 (1). – P. 9–26.
  15. Keefe R.S. et al. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review // J. Clin. Psychiatry. – 2014. – Vol. 75. – P. 864-876.
  16. Kupferberg A., Bicks L., Hasler G. Social functioning in major depressive disorder // Neuroscience & Biobehavioral Reviews. – 2016. – Vol. 69. – P. 313-332.
  17. McIntyre R.S. et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions // Depress Anxiety. – 2013. – 30. – P. 515–527.
  18. McIntyre R.S. et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder (MDD): a meta-analysis of three randomized controlled trials // Int. J. Neuropsychopharmacol. – 2016. – 19. – pyw055.
  19. Millan M.J. et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy // Nat Rev Drug Discov. – 2012. – 11 (2). – P. 141–168.
  20. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. // British Journal of Psychiatry,1979. – Vol. 134, No 4. – P. 382-389.
  21. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis // Int Clin Psychopharmacol. – 1995. – 9 (4). – P. 33–40.
  22. Raddatz R. et al. Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases // Curr Top Med Chem. – 2010. – 10. – P. 153–169.
  23. Rock P.L. et al. Cognitive impairment in depression: a systematic review and meta-analysis // Psychol. Med. – 2014. – 44(10). – P. 2029-2040.
  24. Rosenblat J.D., Kakar R., McIntyre R.S. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials // Int. J. Neuropsychopharmacol. – 2016. – 19(2). – pyv082.
  25. Rush J.A. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report // Am. J. Psychiatry. – 2006. – 163. – P. 1905-1917.
  26. Trivedi M.H., Greer T.L. Cognitive dysfunction in unipolar depression: implications for treatment // J. Affect. Disord. – 2014. – 152-154. – P. 19-27.
  27. Warden D. et al. The STAR*D Project results: a comprehensive review of findings // Curr. Psychiatry Rep. – 2007. – 9. – P. 449-459.

Downloads

Download data is not yet available.